0001209191-22-060585.txt : 20221209
0001209191-22-060585.hdr.sgml : 20221209
20221209193734
ACCESSION NUMBER: 0001209191-22-060585
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221206
FILED AS OF DATE: 20221209
DATE AS OF CHANGE: 20221209
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Donegan Michael C
CENTRAL INDEX KEY: 0001627810
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-00100
FILM NUMBER: 221455938
MAIL ADDRESS:
STREET 1: 6800 BROKEN SOUND PARKWAY NW
STREET 2: THIRD FLOOR
CITY: BOCA RATON
STATE: FL
ZIP: 33487-3507
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TherapeuticsMD, Inc.
CENTRAL INDEX KEY: 0000025743
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 870233535
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 951 YAMATO ROAD, SUITE 220
CITY: BOCA RATON
STATE: FL
ZIP: 33431
BUSINESS PHONE: 561-961-1900
MAIL ADDRESS:
STREET 1: 951 YAMATO ROAD, SUITE 220
CITY: BOCA RATON
STATE: FL
ZIP: 33431
FORMER COMPANY:
FORMER CONFORMED NAME: AMHN, Inc.
DATE OF NAME CHANGE: 20090930
FORMER COMPANY:
FORMER CONFORMED NAME: CROFF ENTERPRISES INC
DATE OF NAME CHANGE: 19970915
FORMER COMPANY:
FORMER CONFORMED NAME: CROFF OIL CO
DATE OF NAME CHANGE: 19920703
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-12-06
0
0000025743
TherapeuticsMD, Inc.
TXMD
0001627810
Donegan Michael C
951 YAMATO ROAD
SUITE 220
BOCA RATON
FL
33431
0
1
0
0
Interim CFO/CAO/VP of Finance
Common Stock
2022-12-06
4
M
0
2300
0.00
A
4288
D
Common Stock
2022-12-06
4
M
0
380
0.00
A
4668
D
Common Stock
2022-12-06
4
M
0
534
0.00
A
5202
D
Common Stock
2022-12-06
4
M
0
262
0.00
A
5464
D
Common Stock
2022-12-06
4
S
0
910
4.775
D
4554
D
Restricted Stock Units
0.00
2022-12-06
4
M
0
2300
0.00
D
Common Stock
2300
0
D
Restricted Stock Units
0.00
2022-12-06
4
M
0
380
0.00
D
Common Stock
380
380
D
Restricted Stock Units
0.00
2022-12-06
4
M
0
534
0.00
D
Common Stock
534
1066
D
Restricted Stock Units
0.00
2022-12-06
4
M
0
262
0.00
D
Common Stock
262
519
D
Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 3,476 shares of issuer common stock in settlement of restricted stock units (RSUs).
The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of $4.76 and $5.29, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.
The RSUs vested in two equal installments on November 24, 2021 and November 24, 2022.
The RSUs vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023.
The RSUs will vest in three equal installments annually beginning July 1, 2022, becoming fully vested on July 1, 2024.
Subject to the reporting person's continuous service, the RSUs will vest in three equal installments annually, beginning September 29, 2022, becoming fully vested on September 29, 2024.
/s/ Michael C. Donegan
2022-12-09